Sangamo Therapeutics (LTS:0R1D) PB Ratio: (As of Aug. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0R1D Sangamo Therapeutics Inc LTS:0R1D
35 GF Score
Price $0.11
GF Value $0.19
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Sangamo Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-07), Sangamo Therapeutics's share price is $0.1099. Sangamo Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 was $-0.05. Hence, Sangamo Therapeutics's PB Ratio of today is .

The historical rank and industry rank for Sangamo Therapeutics's PB Ratio or its related term are showing as below:

During the past 13 years, Sangamo Therapeutics's highest PB Ratio was 35.94. The lowest was 0.39. And the median was 2.98.

LTS:0R1D's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.905
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Sangamo Therapeutics's average Book Value Per Share Growth Rate was -309.10% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Sangamo Therapeutics was 178.90% per year. The lowest was -65.30% per year. And the median was 1.15% per year.

Back to Basics: PB Ratio


Sangamo Therapeutics  (LTS:0R1D) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Sangamo Therapeutics PB Ratio Related Terms


Sangamo Therapeutics PB Ratio Historical Data

* Premium members only.

The historical data trend for Sangamo Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sangamo Therapeutics PB Ratio Chart

Sangamo Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.96 1.70 1.19 9.67 0.00

Sangamo Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.56 7.47 34.12 0.00 0.00

LTS:0R1D vs SER, ABVC, PLRZ: PB Ratio Comparison

For the Biotechnology subindustry, Sangamo Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sangamo Therapeutics PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sangamo Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Sangamo Therapeutics's PB Ratio falls into.


LTS:0R1D
35GF Score
Sangamo Therapeutics Inc LTS:0R1D
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sangamo Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Sangamo Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=0.1099/-0.046
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Is Sangamo Therapeutics (LTS:0R1D) Overvalued in 2026?

Based on GuruFocus' analysis, Sangamo Therapeutics stock appears to be undervalued. The current stock price of $0.11 is trading 42.2% below its estimated GF Value™ of $0.19. GuruFocus considers Sangamo Therapeutics to be Possible Value Trap.

Key valuation signals for LTS:0R1D:

  • PB Ratio:
  • GF Value™: $0.19 vs. price of $0.11 (42.2% below fair value)
  • GF Score™: 35/100 with 5 warning signs

No single metric tells the full story. See the LTS:0R1D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sangamo Therapeutics Business Description

Other Exchanges SGMO:USAGBY:Germany
Address 501 Canal Boulevard, Richmond, CA, USA, 94804
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its neurology development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases and development of novel engineered adeno-associated virus, or AAV, capsids to deliver its therapies to the intended neurological targets. The group's pipeline products are Small Fiber Neuropathy, Prion Disease, Tauopathies, ALS/FTD, Huntington's Disease, Fabry Disease, and Hemophilia A.
35GF Score

Get the complete analysis for LTS:0R1D

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price
$0.19
GF Value